APIMEDS PHARMACEUTICALS US, INC. Research and Development Expense
APIMEDS PHARMACEUTICALS US, INC. (APUS) reported Research and Development Expense of $959.74 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for the quarter ending 2026-06-30 was $959.74K, a 47.25% increase year-over-year.
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for the quarter ending 2026-03-31 was $901.14K.
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for the quarter ending 2025-12-31 was $361.10K.
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for the quarter ending 2025-09-30 was $619.69K.
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for fiscal 2025 was $1.63M.
- APIMEDS PHARMACEUTICALS US, INC. research and development expense for fiscal 2023 was $98.54K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $959.74K 10-Q · filed 2026-08-14 | $1.86M 10-Q · filed 2026-08-14 | $2.22M derived: sum of 3 quarters · filed 2026-08-14 | $2.84M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $901.14K 10-Q · filed 2026-05-26 | $1.26M derived: sum of 2 quarters · filed 2026-05-26 | $1.88M derived: sum of 3 quarters · filed 2026-05-26 | $2.53M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $361.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-05-04 | $980.80K derived: sum of 2 quarters · filed 2026-05-04 | $1.63M derived: sum of 3 quarters · filed 2026-08-14 | $1.63M 10-K · filed 2026-05-04 |
| 2025-09-30 | $619.69K 10-Q · filed 2025-11-12 | $1.27M derived: sum of 2 quarters · filed 2026-08-14 | $1.27M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $651.78K 10-Q · filed 2026-08-14 | $651.78K 10-Q · filed 2026-08-14 | ||
| 2023-12-31 | $98.54K 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |